TCL Archive Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described July 25, 1975
TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive At Its Launch, STAR Trial Inherits Baggage Of Its Predecessor, P-1 Tamoxifin Study June 4, 1999
